DOCSLIB.ORG

Interferon-Based and Interferon-Free New Treatment Options

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interferon-Based and Interferon-Free New Treatment Options Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt am Main Mode of action of Interferons natural immunomodulatory effects IFN-stimulated gene activation Antiviral Apoptotic Immunomodulatory activity activity activity B-cell proliferation Reduced transcription Elevates apoptosis by CTL proliferation Reduced translation multiple mechanisms MHC upregulation Reduced RNA stability Augments NK activity Host-mediated effects are important for DAA combination therapy • Potency and additive effects • Prevention of resistance and viral breakthrough Different types of Interferons Type I Interferons Type III Interferons Broad receptor Receptors distribution distributed throughout various primarily in body tissues epithelial cells and hepatocytes Antiviral effects Antiviral effects Adverse events of Type I IFNs treatment Peg‐Intron • Flu-like symptoms PegIFN‐2a Type III IFNs Potentially fewer • Haematologic IFN omega Peg‐IFN‐ adverse events disorders IFN‐alfa‐2b XL lambda than with type I • Psychiatric Belerofon (Peg‐rIL‐29) interferons symptoms Albuferon Locteron Adapted from 1. Marcello T et al. Gastroenterology 2006;131:1887–98; 2. Muir AJ et al. 2009 AASLD. Abstract 1591; 3. O'Brien TR. Nat Genet. 2009;41:1048–50. PEG-Interferon alfa / Ribavirin Approval studies: efficacy Approval study (n=1530) Approval study (n=1121) Therapy: IFN vs. PEG-IFN alfa 2b Therapy: IFN vs. PEG-IFN alfa 2a 1,0/1,5µg/kgKG per week 180µg per week Ribavirin 1,0-1,2g/die Ribavirin 1,0-1,2g/die 100 100 80 80 54% 56% 60 47% 47% 60 44% 40 40 20 20 0 sustained virologic response (SVR) 0 sustained virologic response (SVR) IFN PEG1,0 PEG1,5 IFN PEG180 Riba Riba Riba Riba Riba Manns et al., Lancet 2001 Fried et al., N Engl J Med 2002 PEG-Interferon alfa / Ribavirin Approval studies: safety Manns et al., Lancet 2001 Fried et al., N Engl J Med 2002 IFN-lambda versus IFN-alfa Distribution of receptors IFN-λ1 IFN-α • IFNs activate antiviral Liver genes required for HCV receptor* receptor* clearance Hepatocytes High High − HCV induces a stronger Endothelial cells Not detected High IFN-lambda response vs Smooth muscle Not detected High IFN-alfa in vitro1 Fibroblasts Not detected High • Receptors for IFN-lambda and -alfa have different Haematopoietic 2 Bone marrow distributions Not detected High progenitors (CD34+) • Reduction in off-target . effects may improve T and NK cells Not detected High tolerability and increase Monocytes Not detected High eligibility and adherence3 B cells High High Central nervous system4 *Based on levels of RNA expression Brain Low High DAA=direct-acting antiviral; IFN=interferon; NK=natural killer Created from 1. Marukian S, et al. Hepatology 2011;54:1913–23; 2. Doyle SE, et al. Hepatology 2006;44:896–906; 3. Muir AJ, et al. Hepatology 2010;52:822–32. 4. Sommereyns C, et al. PLoS Pathog. 2008;4(3):e1000017 PEG-lambda/Riba versus PEG-alfa2a/Riba Clinical Phase 2b study Muir AJ, et al. AASLD 2012. Oral 214. PEG-lambda/Riba versus PEG-alfa2a/Riba Baseline characteristics genotype 1/4 Muir AJ, et al. AASLD 2012. Oral 214. PEG-lambda/Riba versus PEG-alfa2a/Riba Baseline characteristics genotype 1/4 Muir AJ, et al. AASLD 2012. Oral 214. PEG-lambda/Riba versus PEG-alfa2a/Riba Viral kinetics genotype 1/4 Muir AJ, et al. AASLD 2012. Oral 214. PEG-lambda/Riba versus PEG-alfa2a/Riba Virologic response rates genotype 1/4 Muir AJ, et al. AASLD 2012. Oral 214. PEG-lambda/Riba versus PEG-alfa2a/Riba Virologic response rates genotype 2/3 Zeuzem S, et al. EASL 2012. Oral 1435 PEG-lambda/Riba versus PEG-alfa2a/Riba Safety: SAEs, AEs Muir AJ, et al. AASLD 2012. Oral 214. PEG-lambda/Riba versus PEG-alfa2a/Riba Safety: spesific AEs Muir AJ, et al. AASLD 2012. Oral 214. PEG-lambda/Riba versus PEG-alfa2a/Riba Safety: liver-related abnormalities Muir AJ, et al. AASLD 2012. Oral 214. PEG-lambda/Riba versus PEG-alfa2a/Riba Safety: blood cell counts Muir AJ, et al. AASLD 2012. Oral 214. Era of direct antiviral agents Overview on targets within the HCV polyprotein and the host Viral targets Host targets C E1 E2 p7 NS2 NS3 NS4A NS4B NS5A NS5B NS3 NS5A NS5B Cyclophilin A The NS3/4A serine protease Multifunctional membrane- NS5B is an HCV-specific, Host protein involved in HCV associated phosphoprotein is essential for post- RNA-dependent RNA replication through interaction essential component of the 1 translational processing of HCV-RNA replication polymerase with NS5A and the HCV 1 4 HCV polyproteins complex2,3 polymerase Nucleos(t)ide analogue Boceprevir Sofosbuvir, Mericitabine, Telaprevir Daclatasvir VX-135 ABT-450/r, ACH-1625 Ledipasvir Non-nucleoside analogue Alisporivir (currently on hold) Asunaprevir, Simeprevir, ABT-267 BI-207127, ABT-333 SCY-635 Faldaprevir PPI-668 ABT-072, BMS-791325 Danoprevir/r, GS-9451 Tegobuvir, Setrobuvir MK-5172 VX-222, Filibuvir Triple-Therapy based on IFN-lambda PEG-lambda / Ribavirin + Daclatasvir or Asunaprevir HCV Genotype 1a/b, treatment naive patients with chronic hepatitis C Vierling, et al. 63rd AASLD. Poster LB-9 Triple-Therapy based on IFN-lambda PEG-lambda / Ribavirin / Daclatasvir (Asunaprevir) Vierling, et al. 63rd AASLD. Poster LB-9 A first proof-of-principle study Viral eradication with two direct antiviral agents Group A Prior null All oral NS3 PI + NS5A Inh responders with GT-1 HCV 7 (Group A) 6 5 Daclatasvir 60 mg QD + HCV RNA 4 Asunaprevir 600 mg BID 10 3 (n=11) Log 2 LOQ Week 24 1 LOD 01234 6 8 1012 Week Indicates initiation of PegIFN/RBV Frequent viral break-through in subtype 1a pts. No viral break-through / SVR in 2/2 subtype 1b pts. Lok et al., NEJM 2012 IFN-free treatment options Many options with 2, 3, 4, 5 drugs: small studies, high SVR Durati Therapy cirrhosi SVR 4- Regimen n GT on status s 12 (%) (wks.) ABT450r + ABT333 + 79 Naive 1 12 No 98 ABT267 + RBV ABT450r + ABT333 + 95 Null-Resp. 1 12 No 93 ABT267 + RBV BI7127 + Faldaprevir + 362 Naive 1b 28 Yes 83 RBV Daclatasvir + Asunaprevir 32 Naive 1 12 No 94 + BMS791325 Daclatasvir + Asunaprevir 21 Null-Resp. 1b 12 No 90 Daclatasvir + Sofosbuvir 170 Naive 1,2,3 12 - 24 No 88 - 100 Sofosbuvir + RBV 50 Naive 2 / 3 12 Yes 100 Kowdley et al. AASLD 2012, Zeuzem et al. AASLD 2012, Everson et al. AASLD 2012, Lok et al. NEJM 2012, Sulkowsi et al. AASLD 2012, Gane et al. NEJM 2013; Highlights from EASL 2013 Genotype 2/3: less than expected Study design (GT2/3 naïve, Fission study) Week 0 12 24 36 SOF + RBV*, n=256 SVR12 Peg-IFN + RBV* (SOC), n=243 SVR12 *RBV dose 1000-1200 mg/day for SOF + RBV and 800 mg/day for Peg-IFN + RBV. Genotype 2 (28%) or 3 (72%) Expanded inclusion criteria – Targeted 20% enrollment of patients with cirrhosis (>75.000 PLT) IL28B CC (43-44%), cirrhosis (20-21%) Gane et al., EASL 2013; #5 and NEJM 2013 Highlights from EASL 2013 Genotype 2/3: less than expected SVR SOF + RBV Peg-IFN + RBV 98 91 100 82 62 71 80 61 60 34 30 40 SVR12 (%) 20 0 No cirrhosisCirrhosis No cirrhosis Cirrhosis GT 2 GT 3 . 100% on tx response, no viral break-through, failure = relapse . No resistance (deep and phenotypic) Gane et al., EASL 2013; #5 and NEJM 2013 Highlights from EASL 2013 Genotype 1: hope for BOC/TVR failures Study design n = 21 DCV 60 mg QD + SOF 400 mg QD Follow‐up Prior TVR/BOC failures, GT 1a/1b (N = 41) n = 20 DCV 60 mg QD + SOF 400 mg QD + RBV Follow‐up Week SVR12 24 SVR4 Genotype 1a (76-85%) or 1b, non-cirrhotic pts. Failure previous TVR (71-90%) or BOC (10-33%) triple therapy Exclusion of patients with TVR/BOC discont. due to AE Prior break-through or non-response: 57-85% Baseline NS3 resistance mutations: 45-48% Baseline NS5A resistance mutations: 5-10% Sulkowski et al., EASL 2013; #1417 Highlights from EASL 2013 Genotype 1: hope for BOC/TVR failures Virologic response 100 95 100 100 100 100 100 95* 100 91 DCV + SOF 80 80 DCV + SOF patients) 60 + RBV (% Missing 40 LLOQ < 21/41 patients 20 RNA have reached PT HCV Week 24; 0 N = 21 20 21 20 21 20 21 20 21 20 all have achieved SVR Week 2SVRWeek 4 EOT 4 SVR12 24 *1 patient missing at post‐treatment (PT) Week 12: HCV RNA was undetectable at PT Week 4 and at PT Week 24 (preliminary) ■ No serious AE (n=1 hypokalemia), no discont. due to AE, most common AE fatigue & headache Sulkowski et al., EASL 2013; #1417 Summary . Interferon based treatment options have a unique and broad immunemodulatury mode of action without development of resistance . Interferon lambda is at least equaly effective than Interferon alfa with the advantage of less sides effects . Triple-therapies with IFN-lambda, Ribavirin and DAAs (Daclatasvir, Asunaprevir) are well tolerated and highly effective . Interferon free treatment options are currently in phase 2/3 development - high efficacy in easy to treat patients - restricted experience in difficult to treat pts..
Load more

Recommended publications
  • 2019 Icar Program & Abstracts Book
    Hosted by the International Society for Antiviral Research (ISAR) ND International Conference 32on Antiviral Research (ICAR) Baltimore MARYLAND PROGRAM and USA Hyatt Regency BALTIMORE ABSTRACTS May 12-15 2019 ND TABLE OF International Conference CONTENTS 32on Antiviral Research (ICAR) Daily Schedule . .3 Organization . 4 Contributors . 5 Keynotes & Networking . 6 Schedule at a Glance . 7 ISAR Awardees . 10 The 2019 Chu Family Foundation Scholarship Awardees . 15 Speaker Biographies . 17 Program Schedule . .25 Posters . 37 Abstracts . 53 Author Index . 130 PROGRAM and ABSTRACTS of the 32nd International Conference on Antiviral Research (ICAR) 2 ND DAILY International Conference SCHEDULE 32on Antiviral Research (ICAR) SUNDAY, MAY 12, 2019 › Women in Science Roundtable › Welcome and Keynote Lectures › Antonín Holý Memorial Award Lecture › Influenza Symposium › Opening Reception MONDAY, MAY 13, 2019 › Women in Science Award Lecture › Emerging Virus Symposium › Short Presentations 1 › Poster Session 1 › Retrovirus Symposium › ISAR Award of Excellence Presentation › PechaKucha Event with Introduction of First Time Attendees TUESDAY, MAY 14, 2019 › What’s New in Antiviral Research 1 › Short Presentations 2 & 3 › ISAR Award for Outstanding Contributions to the Society Presentation › Career Development Panel › William Prusoff Young Investigator Award Lecture › Medicinal Chemistry Symposium › Poster Session 2 › Networking Reception WEDNESDAY, MAY 15, 2019 › Gertrude Elion Memorial Award Lecture › What’s New in Antiviral Research 2 › Shotgun Oral
    [Show full text]
  • PDF Full-Text
    Review Article Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies Andrew Lee1,2*, Jeremy Rajanayagam1,3 and Mona Abdel-Hady1 1Birmingham Children’s Hospital, Liver Unit, Birmingham, United Kingdom; 2The University of Queensland, School of Medicine, Brisbane, Australia; 3University of Birmingham, School of Infection and Immunity, Birmingham, United Kingdom Abstract remains the most common method of infection in the developing world.1,2 The overall rate of spontaneous viral Viral hepatitis C is responsible for a large burden of disease clearance following childhood infection is low, with the worldwide. Treatment of hepatitis C infection is currently majority of children developing chronic hepatitis C (CHC) undergoing a revolution with the development of new direct (54–86%).2 The clinical course of CHC in children is usually acting antivirals that offer higher cure rates and fewer side silent, with mildly abnormal liver function tests (LFTs) and effects than other medications currently available. Treatment minimal inflammation and fibrosis on histology.2–4 options for children, although well-defined and evidence- Nevertheless, fibrosis tends to progress with time, culminat- based, are limited relative to adults as there are few trials ing in cirrhosis in 5–10% or hepatocellular carcinoma (HCC) regarding the use of these newly developed agents in in 2–5% in adulthood.2,3 Thus, continued efforts to effectively children. With so much optimism in the development of novel treat children and reduce the long-term health and social therapeutic options for hepatitis C, it is timely to review and consequences in pediatric CHC are justified. summarize the current standard of care treatment and indications for treatment of chronic hepatitis C in children.
    [Show full text]
  • Roche Group Development Pipeline
    Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group HY 2013 results Diagnostics Foreign exchange rate information 59 Changes to the development pipeline Q2 2013 update New to Phase I New to Phase II New to Phase III New to Registration 3 NMEs 3 NMEs 3 AIs 1 NME NDA submissions EU RG7410 in metabolic diseases RG7853 ALK inhibitor in NSCLC RG1273 Perjeta in HER2-positive and US RG7745 in infectious diseases RG7446 PD-L1 MAb in mNSCLC gastric cancer RG7159 obinutuzumab in CLL RG7842 in solid tumors RG7601 Bcl-2 inh in CLL RG435 Avastin in recurrent cervical 1 AI submission to FDA 3 AIs relapsed/refractory 17pdel cancer RG1273 Perjeta in neoadjuvant RG7446 PD-L1+Zelboraf in RG1569 Actemra in giant cell HER2-positive breast cancer metastatic melanoma arteritis RG7446 PD-L1 + Avastin in solid tumors RG7446 PD-L1 in solid tumors Removed from Removed from Phase I Removed from Phase II Removed from Phase III Registration 1 NME due to selection of 1 NME 2 NMEs 1 NME EU approval alternative molecule RG7160 imgatuzumab (GA201, RG1439 aleglitazar CV risk RG3616 Erivedge in advanced RG7112 MDM2 ant. in solid and EGFR MAb) in solid tumors reduction post ACS in type 2 basal cell carcinoma hematological tumors 2 AIs diabetes; complete programme 1 AI EU+US approval RG3638 onartuzumab in triple-neg terminated RG1569 RoActemra/Actemra in mBC 1st/2nd line SST arbaclofen in fragile X syndrome polyarticular
    [Show full text]
  • Setrobuvir | Medchemexpress
    Inhibitors Product Data Sheet Setrobuvir • Agonists Cat. No.: HY-13247 CAS No.: 1071517-39-9 Molecular Formula: C₂₅H₂₅FN₄O₆S₂ • Molecular Weight: 560.62 Screening Libraries Target: DNA/RNA Synthesis; HCV; SARS-CoV Pathway: Cell Cycle/DNA Damage; Anti-infection Storage: Please store the product under the recommended conditions in the Certificate of Analysis. BIOLOGICAL ACTIVITY Description Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS- CoV-2 RdRp and induces RdRp inhibition[1][2]. In Vitro Setrobuvir (ANA598) is a non-nucleoside inhibitor that binds to the palm pocket of the HCV polymerase and has an EC50 against HCV genotype 1b/Con1-containing subgenomic replicons in the nanomolar range. Setrobuvir appears to inhibit both de novoinitiated RNA synthesis and primer extension, and its activity is unchanged by the presence of mutations that modify the activity of thumb-binding non-nucleoside inhibitors[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. REFERENCES [1]. Yi G, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012;56(2):830- 837. [2]. Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silicoperspective [published online ahead of print, 2020 May 6]. J Biomol Struct Dyn. 2020;1-9. McePdfHeight Caution: Product has not been fully validated for medical applications.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Poveda E Aplicaciones Clínicas Resistencias HCV 1Enerovigo 2014
    Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical development DAA family NS5B nucleos(t)ide NS5B non-nucleoside analogues NS3/4A inhibitors NS5A inhibitors analogues inhibitors inhibitors ∗∗∗ Sofosbuvir (GS-7977) ̷̷̷ Deleobuvir (BI-207127; NNI-site 1 inhibitor) Telaprevir Daclatasvir (BMS-790052) Mericitabine (RG-7128) ABT-333 (NNI-site 3 inhibitor) Boceprevir ∗∗∗ Ledipasvir (GS-5885) VX-135 IDX-184 VX-222 (NNI-site 2 inhibitor) Simeprevir (TMC-435) ̷̷̷ ABT-267 VX-135 ABT-072 (NNI-site 3 inhibitor) Faldaprevir (BI-2011335) MK-8742 GS-6620 Setrobuvir (ANA-598; NNI-site 3 inhibitor) Asunaprevir (BMS-650032) Samatasvir (IDX-719) INX-189 GS-9669 (NNI-site 2 inhibitor) Vaniprevir (MK-7009) ACH-3102 Tegobuvir (GS-9190; NNI-site 5 inhibitor) Danoprevir (RG-7227) Filivubir (PF-868554; NNI-site 2 inhibitor) Sovaprevir (ACH-1625) ABT-450/r GS-9451 MK-5172 ∗∗∗Approved by the FDA and EMA in 2011. Adapted from Poveda E et al. Future Virology 2012 Ϯ Approved by the FDA November/December 2013. Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic, Higher SVR, Eventually Oral for all patients 2013 2014 2015 Genotype 2&3 Genotype 2 Genotypes 1-4 P/R Sofosbuvir+RBV 12 weeks Sofosbuvir+Ledipasvir ± RBV Genotypes 1 Genotype 3 ABT-450+ABT-267+ABT-333 Telaprevir + P/R Sofosbuvir+RBV 24 weeks +RBV Boceprevir + P/R Genotypes 1-4 Daclatasvir+Asunaprevir Sofosbuvir + P/R Genotypes 1 Simeprevir + P/R HCV Resistance to DAA During DAA-based treatment: ■ Rapid selection of resistance mutation may occur, eventually leading to viral break-through.
    [Show full text]
  • HEPATITIS C MEDICINES Technology and Market Landscape
    2015 HEPATITIS C MEDICINES Technology and Market Landscape FEBRUARY 2015 UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211 Geneva 27 Switzerland T +41 22 791 55 03 F +41 22 791 48 90 [email protected] www.unitaid.org UNITAID is hosted and administered by the World Health Organization © 2015 World Health Organization (Acting as the host organization for the Secretariat of UNITAID) The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind either expressed or implied. The responsibility and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. This report was prepared by Mike Isbell and Renée Ridzon (Ahimsa) and Karin Timmermans (UNITAID). All reasonable precautions have been taken by the authors to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C
    30 Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C Andrew Aronsohn, MD1 Donald Jensen, MD1 1 Center for Liver Disease, Section of Gastroenterology, Hepatology Address for correspondence Andrew Aronsohn, MD, Center for Liver and Nutrition, University of Chicago Medical Center, Chicago, Illinois Disease, Section of Gastroenterology, Hepatology and Nutrition, 5841 South Maryland Avenue, MC 7120, Chicago, IL 60637 Semin Liver Dis 2014;34:30–36. (e-mail: [email protected]). Abstract Direct acting antiviral agents have revolutionized hepatitis C (HCV) therapy. Many agents that are either currently available or undergoing investigation offer higher rates of sustained virologic response, reduced toxicity and shorter duration of therapy when compared to traditional treatment consisting of pegylated interferon and ribavirin. Keywords Although interferon free therapy may be a preferred option, some patients may still ► hepatitis C require an interferon based regimen to ensure efficacy. In this review, we discuss ► hepatitis C therapy therapeutic strategies which utilize various combinations of protease inhibitors, NS5A ► direct-acting antiviral inhibitors, nucleotide polymerase inhibitors and non-nucleoside polymerase inhibitors agents along with pegylated interferon in the treatment of chronic HCV. In 2011, the first direct-acting antiviral agents (DAAs) became complex is involved in decreasing activity of type 1 IFN available for use in the treatment of chronic hepatitis C. In though cleavage of IFN-B promoter
    [Show full text]
  • Full PDF of 2013 Pipeline Report
    ABOUT HIV i-BASE HIV i-Base is a London-based HIV treatment activist organization. HIV i-Base works in the United Kingdom and internationally to ensure that people living with HIV are actively engaged in their own treatment and medical care and are included in policy discussions about HIV treatment recommendations and access. www.i-base.info ABOUT TAG The Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. www.treatmentactiongroup.org 2013 PIPELINE REPORT HIV, HEPATITIS C VIRUS (HCV), AND TUBERCULOSIS (TB) DRUGS, DIAGNOSTICS, VACCINES, PREVENTIVE TECHNOLOGIES, RESEARCH TOWARD A CURE, AND IMMUNE-BASED AND GENE THERAPIES IN DEVELOPMENT By Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, and Tracy Swan Edited by Andrea Benzacar JUNE 2013 HIV i-BASE/TREATMENT AcTION GROUP AUTHORS Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, and Tracy Swan EXECUTIVE EDITOR Andrea Benzacar EDITORS Tim Horn and Scott Morgan DESIGNER Lei Chou ACKNOWLEDGMENTS i-Base thanks the Monument Trust and UNITAID for support for this work. Thanks to the TAG staff, board, and donors for supporting the production of the 2013 Pipeline Report. HIV i-Base Treatment Action Group 4th Floor, 57 Great Suffolk Street 261 Fifth
    [Show full text]
  • Alzheimer's Disease
    Wall Street View Pharmaceutical Executives’ 2013 © yright ibution p istr Co l D nload, rcia n dow Pipelinem Re eeprs caort m us use Co orised sonal or . Auth or per ale hibited copy f r S se pro ingle t fo ised u rint a s AlzhNeimoer’s Daiustehaosre: Movi nangd F porward Un y, view displa Drug Name Company Phase Launch Date Sales Potential Solanezumab III N/A N/A Gantenerumab II/III N/A N/A Hepatitis C: The More the Merrier Drug Name Company Phase Launch Date Sales Potential Sofosbuvir III 2014 Blockbuster Simeprevir/Daclatasvir III 2014/2015 Minibuster ABT-450 III 2015 Blockbuster Setrobuvir/Danoprevir/ II 2015 Minibuster Mericitabine Sovaprevir II N/A N/A Rheumatoid Arthritis: Return of the DMARDS Drug Name Company Phase Launch Date Sales Potential Tofacitinib Preregistration 2012/2013 Blockbuster Baricitinib II N/A N/A Fostamatinib III 2014 Minibuster GLPG 0634 II 2017 N/A Canadian Pharmaceutical Marketing l June/July 2013 7 Wall Street View Cancer: Improving on Innovation Drug Name Company Phase Launch Date Sales Potential GDC-0973 III N/A N/A Dabrafenib Preregistered 2013 Minibuster Trametinib Preregistered 2013 Minibuster Nivolumab II 2015 Blockbuster Trastuzumab Emtansine Preregistration 2013 Blockbuster 3 Radium-223 Chloride III N/A Blockbuster ARN 509 I/II N/A N/A Ponatinib Preregistration 2013 Minibuster Ibrutinib III 2014 Blockbuster Diabetes: Incremental Improvement Drug Name Company Phase Launch Date Sales Potential Tresiba Preregistered 2013 Blockbuster Ryzodeg Preregistered 2013 Blockbuster LY2605541 & LY2963016 III 2015
    [Show full text]
  • New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development
    22 New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development Jean-Michel Pawlotsky, MD, PhD1,2 1 National Reference Center for Viral Hepatitis B, C and D, Department Address for correspondence Jean-Michel Pawlotsky, MD, PhD, of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, Department of Virology, Hôpital Henri Mondor, 51 avenue du Maréchal France de Lattre de Tassigny, 94010 Créteil, France 2 INSERM U955, Créteil, France (e-mail: [email protected]). Semin Liver Dis 2014;34:22–29. Abstract The development of new models and tools has led to the discovery and clinical development of a large number of new anti-hepatitis C virus (HCV) drugs, including direct-acting antivirals and host-targeted agents. Surprisingly, curing HCV infection appears to be easy with these new drugs, provided that a potent drug combination with a high barrier to resistance is used. HCV infection cure rates can be optimized by combining drugs with synergistic antiviral effects, tailoring treatment duration to the patients’ needs, and/or using ribavirin. Two HCV drugs have been approved in 2011— Keywords telaprevir and boceprevir, both first-wave, first-generation NS3-4A protease inhibitors, ► hepatitis C virus two others in 2013/2014—simeprevir, a second-wave, first-generation NS3-4A protease ► direct-acting inhibitor, and sofosbuvir, a nucleotide analogue inhibitor of the viral polymerase. antivirals Numerous other drugs have reached phase II or III clinical development. From 2015 ► host-targeted agents and onwards, interferon-containing regimens will disappear, replaced by interferon-free ► simeprevir regimens yielding infection cure rates over 90%.
    [Show full text]